Anti-CD38 Antibody Treating APS With Thrombocytopenia
Phase 2
Recruiting
- Conditions
- Antiphospholipid SyndromeThrombocytopenia
- Interventions
- Drug: Anti-CD38 antibody Injection
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 10
- Registration Number
- NCT05983952
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
Phase 2
Recruiting
- Conditions
- Plasma Cell Leukemia
- Interventions
- Biological: anti-BCMA CAR-TDrug: VRD-based regimen
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 20
- Registration Number
- NCT05979363
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia
Phase 2
Recruiting
- Conditions
- Severe Aplastic Anemia
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-08-01
- Target Recruit Count
- 43
- Registration Number
- NCT05975996
- Locations
- 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Peripheral T Cell LymphomaEpigenetic Repression
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2024-12-30
- Target Recruit Count
- 37
- Registration Number
- NCT05958719
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia
Not Applicable
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 90
- Registration Number
- NCT05941585
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-03-12
- Target Recruit Count
- 36
- Registration Number
- NCT05925504
- Locations
- 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT
Phase 2
Not yet recruiting
- Conditions
- The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
- Interventions
- Drug: CD25 prophylaxis
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2023-06-28
- Target Recruit Count
- 20
- Registration Number
- NCT05923814
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
Phase 4
Not yet recruiting
- Conditions
- The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 21
- Registration Number
- NCT05914675
Ruxolitinib as GVHD Prophylaxis in AA Patients
Phase 2
Not yet recruiting
- Conditions
- The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 46
- Registration Number
- NCT05914714
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Phase 2
Recruiting
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 42
- Registration Number
- NCT05914662
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath